Development and validation of a programmed cell death index to predict the prognosis and drug sensitivity of gastric cancer

2024

New Index to Predict Gastric Cancer Outcomes

Sample size: 323 publication 10 minutes Evidence: high

Author Information

Author(s): Lin Feizhi, Chen Xiaojiang, Liang Chengcai, Zhang Ruopeng, Chen Guoming, Zheng Ziqi, Huang Bowen, Wei Chengzhi, Zhao Zhoukai, Zhang Feiyang, Chen Zewei, Ruan Shenghang, Chen Yongming, Nie Runcong, Li Yuangfang, Zhao Baiwei

Primary Institution: State Key Laboratory of Oncology in South China, Department of Gastric Surgery, Sun Yat-Sen University Cancer Center, Guangdong Provincial Clinical Research Center for Cancer, Guangzhou, China

Hypothesis

Can a programmed cell death index (PCDI) predict prognosis and drug sensitivity in gastric cancer patients?

Conclusion

The PCDI model effectively predicts clinical prognosis and drug sensitivity in gastric cancer, aiding personalized treatment strategies.

Supporting Evidence

Patients with higher PCDI scores had poorer prognoses.
A high-performance nomogram integrating PCDI with clinical features was established.
Single-cell analysis suggested PCDI is linked to critical components of the tumor microenvironment.
Patients with high PCDI scores exhibited resistance to standard chemotherapy and immunotherapy.
Targeted treatments like NU7441, Dasatinib, and JQ1 may benefit high PCDI patients.

Takeaway

Researchers created a new tool to help doctors understand how likely patients with stomach cancer are to respond to treatments based on their cell death patterns.